Sasano H, Suzuki T, Niikura H, Kaga K, Sato S, Yajima A, Rainey W E, Nagura H
Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.
Mod Pathol. 1996 Apr;9(4):386-91.
Type 1 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) is an estrogen-metabolizing enzyme that catalyzes the conversion of estrone to the more biologically potent estradiol. We examined the immunolocalization of 17 beta-HSD in five specimens of normal human ovary and in 51 specimens of common epithelial tumors of the ovary to study the expression of 17 beta-HSD in these ovarian neoplasms. 17 beta-HSD immunoreactivity was detected in granulosa cells of dominant preantral follicles but not in the surface epithelium of the normal cycling human ovary. In 12 patients, the enzyme was not expressed in tumor cells of benign cystadenoma. 17 beta-HSD was immunolocalized in the cytoplasm of four specimens (50%) of eight of tumors of low malignant potential and in 20 specimens (67%) of 30 of invasive carcinoma. 17 beta-HSD immunoreactivity was also observed in nonluteinized stromal cells of mucinous tumors (two adenomas of six, three tumors of five with low malignant potential, and two of 10 invasive carcinomas) but not in other histologic types. Type 1 17 beta-HSD expression, therefore, correlated with malignant transformation of the surface epithelium of the human ovary, supporting a possible role in its progression by increasing in situ estradiol concentration.
1型17β-羟类固醇脱氢酶（17β-HSD）是一种雌激素代谢酶，可催化雌酮转化为生物活性更强的雌二醇。我们检测了17β-HSD在5例正常人类卵巢标本和51例卵巢常见上皮性肿瘤标本中的免疫定位，以研究17β-HSD在这些卵巢肿瘤中的表达情况。在优势窦前卵泡的颗粒细胞中检测到17β-HSD免疫反应性，但在正常月经周期的人类卵巢表面上皮中未检测到。在12例患者中，该酶在良性囊腺瘤的肿瘤细胞中未表达。17β-HSD在8例低恶性潜能肿瘤中的4例（50%）以及30例浸润性癌中的20例（67%）的细胞质中呈免疫定位。在黏液性肿瘤的非黄体化基质细胞中也观察到17β-HSD免疫反应性（6例腺瘤中的2例、5例低恶性潜能肿瘤中的3例以及10例浸润性癌中的2例），但在其他组织学类型中未观察到。因此，1型17β-HSD的表达与人类卵巢表面上皮的恶性转化相关，通过增加局部雌二醇浓度支持其在肿瘤进展中可能发挥的作用。
